Heparin sodium compliance to the new proposed USP monograph: Elucidation of a minor structural modification responsible for a process dependent 2.10ppm NMR signal

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 2, 2011, Pages 337-344

  Mourier, Pierre A J ^a   Guichard, Olivier Y ^a   Herman, Fréderic ^a   Viskov, Christian ^a  

^a SANOFI   (France)

Author keywords

Heparin; Heparinase I; NMR; Oversulfated chondroitin sulfate

Indexed keywords

HEPARIN; HEPARIN LYASE; OLIGOSACCHARIDE; PERMANGANATE POTASSIUM; POLYSACCHARIDE;

ARTICLE; CONTROLLED STUDY; DEPOLYMERIZATION; DRUG PURIFICATION; DRUG STRUCTURE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; ANTICOAGULANTS; CHONDROITIN SULFATES; DRUG CONTAMINATION; FLAVOBACTERIUM; GLYCOSAMINOGLYCANS; GUIDELINE ADHERENCE; HEPARIN; HEPARIN LYASE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; OLIGOSACCHARIDES; OXIDANTS; PHARMACEUTICAL PREPARATIONS; PHARMACOPOEIAS AS TOPIC; POTASSIUM PERMANGANATE; SWINE; UNITED STATES;

EID: 78650201747     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.09.011     Document Type: Article

References (9)

1. Heparin sodium monograph in pharmacopeial forum, vol. 35(5) [Sept-Oct 2009] p. 3. 1H NMR spectrum. Signal 1 is observed at 5.42ppm (H1 of GlcNAc/GlcNS,6S) and signal 2 at 5.21ppm (H1 of IdoA 2S). The ppm values of these signal should not differ by more than +0.03ppm.
2. Guerrini M., Beccati D., Shriver Z., Naggi A., Viswanathan K., Bisio A., Capila I., Lansing J.C., Guglieri S., Fraser B., Al-Hakim A., Sibel Gunay N., Zhang Z., Robinson L., Buhse L., Nasr M., Woodcock J., Langer R., Venkataraman G., Linhardt R.J., Casu B., Torri G., Sasisekharan R. ,Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat. Biotechnol. 2008, 26:669-675.
3. Mourier P.A.J., Viskov C. Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethylammonium dynamically coated stationary phases. Anal. Biochem. 2004, 332:299-313.
4. Thanawiroon C., Rice K.G., Toida T., Linhardt R.J. Liquid chromatography/mass spectrometry sequencing approach for highly sulfated heparin-derived oligosaccharides. J. Biol. Chem. 2004, 279:2608-2618.
5. Schleucher J., Schwendinger M., Sattler M., Schmidt P., Schedletzky O., Glaser S.J., Sorenson O.W., Griesinger C.J. A general enhancement scheme in heteronuclear multidimensional NMR employing pulsed field gradients. Biomol. NMR 1994, 4:301-306.
6. Summers M.F., Marzilli L.G., Bax A.J. Complete proton and carbon-13 assignments of coenzyme B12 through the use of new two-dimensional NMR experiments. J. Am. Chem. Soc. 1986, 108:4285-4294.
7. P.A.J. Mourier, C. Viskov, Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin or heparin products, United States, Patent Application Publication, US 2005/0215519 (September 29, 2005).
8. Sugahara K., Tsuda H., Yoshida K., Yamada S. Structure Determination of the octa- and decasaccharide sequences isolated from the carbohydrate-protein linkage region of porcine intestinal heparin. J. Biol. Chem. 1995, 270(39):22914-22923.
9. Merchant Z.M., Kim Y.S., Rice K.G., Linhardt R.J. Structure of heparin-derived tetrasaccharides. Biochem. J. 1985, 229:369-377.